Shopping Cart
- Remove All
Your shopping cart is currently empty
AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $147 | In Stock | |
| 5 mg | $348 | In Stock | |
| 10 mg | $475 | In Stock | |
| 25 mg | $667 | In Stock | |
| 50 mg | $887 | In Stock | |
| 100 mg | $1,220 | In Stock | |
| 200 mg | $1,630 | In Stock |
| Description | AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia. |
| Targets&IC50 | HT1080 (chondrosarcoma cell lines):1 nM, IDH1-R132H homodimer (mutation):6 nM |
| In vivo | AGI-14100 (50 mg/kg; oral; single; female nude BALB/c mice) inhibition robust tumor 2-HG was achieved 12 hours post-dose demonstrating desirable in vivo results.[1] AGI-14100 had decent oral pharmacokinetics (PK) properties in rats (F =44 %), dogs (F =18 %), and cynomolgus monkeys (F =43 %).[1] |
| Synonyms | AGI 14100 |
| Molecular Weight | 599.96 |
| Formula | C29H22ClF4N5O3 |
| Cas No. | 1448346-43-7 |
| Smiles | N([C@H](C(NC1CC(F)(F)C1)=O)C2=C(Cl)C=CC=C2)(C(=O)[C@H]3N(C(=O)CC3)C4=CC(C#N)=CC=N4)C5=CC(F)=CC(F)=C5 |
| Relative Density. | 1.51 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (83.34 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.